Scrip’s Rough Guide To Targeted Protein Degradation
Drugging The Undruggable
Executive Summary
By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. Scrip takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.
You may also be interested in...
Seagen And Nurix Hope To Pioneer A New Class Of Degrader-Antibody Conjugates
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.
Can China Innovate? Degron Aims For First-In-Class TPD Therapies
Fresh out of an impressive new round of financing and armed with $32m, Shanghai's Degron Therapeutics is aiming for nothing but first-in-class treatments. Its co-founder and CSO shares views on creating original innovative drugs from inside China in an exclusive interview with Scrip.
Proteome-Focused ProFound Emerges From Flagship Pioneering
The company says its platform technology has uncovered “tens of thousands” of previously undiscovered proteins.